Prognosis
Sputnik Vaccine Output to Surge on New Pact With Drugmaker in India
- Gland Pharma to supply 252 million doses by end-2021: filing
- Russia wants to administer shots to one in 10 people globally
Photographer: Andrey Rudakov/Bloomberg
This article is for subscribers only.
Russia will triple production of its Sputnik V vaccine in India following a new deal that strengthens Moscow’s pledge to inoculate a tenth of the global population.
Gland Pharma Ltd., a Chinese-owned firm based in the southern Indian city of Hyderabad, on Tuesday said it will supply 252 million shots of Sputnik V from the fourth quarter of this year. This adds to the more than 100 million doses planned from other Indian manufacturers.